An assessment of maximal androgen blockade in the treatment of advanced prostatic carcinoma

Oncology Research and Treatment

Volumn 19, Issue 4, 1996, Pages 302-307

  Altwein, J E ^a   Silchinger, J ^a  

^a KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

Author keywords

Leuprorelin; Maximal androgen blockade; Prostate cancer

Indexed keywords

FLUTAMIDE; GOSERELIN; LEUPRORELIN; NILUTAMIDE;

ADVANCED CANCER; HUMAN; MALE; PROSTATE CARCINOMA; REVIEW;

EID: 0029818518     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218819     Document Type: Article

References (55)

1. Bracci U, Do Silverio F: Role of cyproterone acetate in urology: in Martini L, Motta M (eds): Androgens and Antiandrogens, New York, Raven Press, 1977, pp 333-339.
2. Veterans Administration Co-Operative Urological Research Group: Treatment and survival of patients with cancer of the prostate, Surg Gynecol Obstet 1967:124:1011-1017.
3. Robinson MRG: A further analysis of European Organization for Research and Treatment of Cancer protocol 30805: Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstil-bestrol, Cancer 1993:72:3855-3857.
4. Ncri RO: Anliandrogens: Preclinical and clinical studies, Urol Symp 1994;44:53-60.
5. Labrie F, Dupont A, Belanger A, Cusan L, Lacour-ciere Y, Monfelte G, Laberge JG, Emond JP, Fazekas ATA, Raynaud JP, Husson JM: New hormonal therapy in prostatic carcinoma: Combined treatment with an LH-RH-agonist and an antiandrogen, Clin Invest Med 1982:5:267-275.
6. Prostate Cancer Trialist’s Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients, Lancet 1995:346: 265-269.
7. Harper ME, Pike A, Peeling WB: Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro, J Endocrinol 1994:80: 1065-1070.
8. Geller J, Albert J, Loza D, Geller S, Stocltzing W, dc la Vega D: DHT concentrations in human prostate cancer tissue, J Clin Endocrinol Melab 1978:46: 440-444.
9. Geller J, Albert JD: Comparison of various hormonal therapies for prostatic carcinoma, Semin Oncol 1983;10(suppl 4):34-39.
10. Labrie F: Combination therapy with flutamide and (D-Trp6) LHRH ethylamide in advanced (stage D and Dl) previously untreated prostate cancer; in Motta M, Serio M (eds): International Symposium on Hormonal Therapy of Prostate Disease, London, Mcdicom, 1988, pp 99-104.
11. Landström M, Bergh A, Tomic R, Damber JE: Estrogen Treatment Combined With Castration Inhibits Tumor Growth More Effectively Than Castration Alone in the Dunning R3327 Rat Prostatic Adenocarcinoma, Prostate 1990:17:57-68.
12. Leuprolidc Study Group: Leuprolide versus diethyl-stilbestrol for metastatic prostate cancer, N Engl J Med 1984:311:1281-1286.
13. Brewster SF: Advanced prostate cancer: What’s new in hormonal manipulation? Br J Hosp Med 1993:49:710-715.
14. Crawford ED, Smith JA Jr, Soloway MS, Lange PH, Lynch DF, Al-Juburi A, Bracken RB, Heyden N, Bertagna C: Treatment of stage D2 prostate cancer with leuprolide and anandron compared to leuprolide and placebo: in Murphy G, Khoury S, Chatelain C, Denis L (eds): Recent Advances in Urological Cancers: Diagnosis and Treatment, Paris, Scientif Commun Int, 1990, pp 27-29.
15. Crawford ED, Eisenberger MA, McLeod DG, Dorr FA, Davis A: A controlled trial of leuprolide with and without flutamid in prostatic carcinoma, N Engl J Med 1989:321:419-424.
16. Bono AV, Brausi M, Ferrari P, Ciibba A, di Silverio F, Galli L, Camp B, Catanzaro F, Civino A, Cosciani S: Italian Leuprolide Group, Maximal androgen withdrawal vs chemical castration in advanced prostatic cancer: Results of an Italian multicenter study (meeting abstract), SIU Congress Sydney, 1994:23: A689.
17. Boccon-Gibod L: Nonsteroidal Antiandrogen Monotherapy of Metastatic Cancer of the Prostate, Eur Urol 1993:24:77-80.
18. Neri R, Kasscm N: Biological and clinical properties of antiandrogens; in Bresciani F, King RJB, Lipp-man ME, Nmer M, Raynaud JP (eds): Progress in Cancer Research and Therapy, New York, Raven Press, 1984, pp 507-518.
19. Chang A, Yeap B, Blum R, Hahn R, Khanna O, Fisher H, Witte R, Trump D: A double blind randomized study of primary treatment for stage D2 prostate cancer; diethylstilbestrol (DES) versus flutamide (F), Proc ASCO 1992:1 LA202.
20. Lund F, Rasmussen F: Flutamide versus stilboestrol in the management of advanced prostatic cancer, a controlled prospective study, Br J Urol 1988:61: 140-142.
21. Boccon-Gibod L, Fournier G, Bot-Ret P, et al: Flutamide versus orchidectomy in patients with metastatic prostate carcinoma (abstract). J Urol 1992: 147:417.
22. 1], Br J Urol 1993:72:629-634.
23. Schröder FH, Lock TM, Chadha DR: Metastatic cancer of the prostate managed with buserelin versus buserclin plus cyproteron acetate, J Urol 1995: 17:912-918.
24. Waxman J: Anti-androgens in treatment of prostate cancer, Lancet 1995;346:1030-1031.
25. Labrie F: Letters to the Editor, Anti-androgens in treatment of prostate cancer, Lancet 1995:346: 1030-1031.
26. Crawford ED, DeAntonio EP, Labrie F, Schröder FH, Geller J: Therapeutic Controversies: Endocrine Therapy of Prostate Cancer: Optimal Form and Appropriate Timing, J Clin Endocrinol and Metabol 1995:80:1062-1078.
27. Daneshgari F, Crawford ED: Endocrine therapy of advanced carcinoma of the prostate, Cancer 1993: 71:1089-1097.
28. Crawford ED: Changing Concepts in the Management of Advanced Prostate Cancer, Urol Symp 1994:4A: 67-74.
29. Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwiek DG: Decrease of prostatic intraepithélial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy, Urology 1994:55:91-95.
30. Peyrottes A, Beniziri E, Chevallier D, Vole P, Michiels JF, Amiel J, Toubol J: Prostatique radical après blocage androgènique complet pour cancer de stade B2 et C, J Urologie 1994:100:290-293.
31. Civantos F, Marcial MA, Banks F.R, Ho CK, Speights VO, Drew PA, Murphy WM, Soloway MS: Pathology of Androgen Deprivation Therapy in Prostate Carcinoma, Cancer 1995;75:1634-1641.
32. Flamm J, Fischer M, Höltl W, Pflüger H, Tomschi W: Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate, Eur Urol 1991;19:192-195.
33. Stein A, deKernion JB, Smith RB, Dorcy F, Patel H: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer, J Urol 1992;147:942-946.
34. Kennedy TJ, Sonneland AM, Marlett MM, Troup RH, Labrie F: Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer, J Urol 1992;147:891-893.
35. Pinaull S, Monfette G, Tetu B, Dupont A, Gagnon J, Labrie F: Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide, Urology 1992:39:254-261.
36. Solomon IL McHugh TA, Dorr RP, Lee F, Siders DB: Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy, Clin Invest Med 1993:16: 532-538.
37. Macfarlane MT, Abi-Aad A, Stein A, Danella J, Belldegrun A, DeKernion JB: Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer, J Urol 1993:150:132-134.
38. Pummer K, Crawford ED, Daneshgari F, Andros B, Pfister S, Miller GJ: Hormonal pretreatment does not affect the final pathologic stage in locally advanced prostate cancer, Urol Symp 1994:44:38-42.
39. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lomay M, Tetu B, Emond J, Candas B: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial, Clin Invest Med 1993:16:499-509.
40. Witjes WPJ, Oostcrhof GON, Schaafsma HE, Debruyne FMJ: Current Status of Neoadjuvant Therapy in Localized Prostate Cancer, Prostate 1995:27:297-303.
41. Jakse G: Prostate cancer stage T2 (B2/B3), Does down-staging with hormonal deprivation facilitate surgery and lower the rate of positive margins? The audience's opinion and the chairman's comments; in Murphy G, Khoury S, Chatelain C, Denis L (eds): 4th Int Symp on Recent Advances in Urological Cancer, Jersey, Scienlif Commun Int 1993, pp 291-292.
42. Altwein JE, Leitenberger A: Adjuvant therapy following radical prostatectomy, Akt Urol 1990:21(suppl): 13-17.
43. Zincke H, Bergslrahl EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM, Barrett DM, Rife CC, Gonchoroff NJ: Stage D prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment, Cancer 1992:70:311-323.
44. Brasilis KG, Davi RC, Nelson E, Civantos, F, Soloway MS: Squamous cell carcinoma of the prostate: A transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and futamide, Urology 1995:45: 329-331.
45. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer, N Engl J Med 1995;332:1393-1398.
46. Wilson JD: Ihe promiscuous receptor, Prostate cancer comes of age, N Engl J Med 1995;332:1440-1441.
47. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory' prostate cancer, J Clin Oncol 1987:11:1566-1572.
48. Small FJ, Carroll PR: Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome, Urology 1994:43:408-410.
49. Crawford ED, DeAntoni EP: Combined Androgen Blockage: An Idea whose Time has Come: in Murphy G, Khoury S, Chatelain C, Denis L (eds): 4th International Symposium on Recent Advances in Urological Cancer, Jersey, Scientif Commun Int, 1993, pp 260-268.
50. Bennett CL, McLeod DG, Hillner BE: Estimating the cost-effectiveness of total androgen blockade for stage D-2 prostate cancer, Proc Annu Meet Am Soc Clin Oncol 1994:13: A724.
51. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer, Urology 1995:45: 745-752.
52. Soloway MS: Combination therapy with bicalutamide 50 mg (abstract), Prostate cancer: Current issues, new' approaches, London, October 19-21.1995.
53. Bruchovsky N: Androgens and antiandrogens: in Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds): Cancer Medicine, Philadelphia, Lea & Febiger, 1993, pp 884-896.
54. Bertagna C, De Gery A, Hüchcr M, Francois JP, Zanirato J: Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostate cancer, A meta-analvsis of 7 randomized double-blind trials (1.056 patients), Br J Urol 1994:73:396-402.
55. Caubet JF, Tosteson TD, Doug EW, Naylon E, Emstoff MS, Ross S: Meta-analysis of published randomized clinical trials for MAB in prostate cancer, Proc, ASCO 1996;15: A654.